Alan D. Friedman, MD
Professor of Oncology & Pediatric, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Dr. Friedman earned his undergraduate degree in Biochemistry at the University of California at Berkeley (1979) and his medical degree from Harvard Medical School (1983). He undertook pediatric residency at Children’s Hospital, Boston (1983-1986), followed by a fellowship in pediatric hematology/oncology at Johns Hopkins Hospital (1986-1989), after which he joined the Pediatric Oncology faculty. Dr. Friedman’s laboratory has mainly studied regulation of normal and malignant hematopoietic development by transcription factors and cytokine signals. In particular he has focused his efforts on the roles of RUNX1, C/EBPa, and G-CSF versus M-CSF signals on granulocyte versus monocyte myeloid lineage determination and on how RUNX1 oncoproteins or CEBPA point mutants, each expressed in human acute myeloid leukemia (AML), perturbs normal hematopoiesis. In addition, over the last several years his group has investigated whether manipulating myeloid transcription factors alters tumor-associated macrophages in a beneficial manner in solid tumors. He is a past Searle Scholar and Leukemia and Lymphoma Society Scholar and National Institutes of Health Hematopoiesis Study Section member and has authored more than 100 scientific articles, reviews, and book chapters.